VANCOUVER, British Columbia -- The novel multitarget stool RNA test (ColoSense) showed high sensitivity for detecting colorectal neoplasia among adults ages 45 and older, according to the phase III ...
CINCINNATI, June 20, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today two new ...
A simple stool test could soon revolutionize chronic diarrhoea diagnosis in India. Researchers found measuring bile acids in ...
ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, announced the publication of a ...
A study has used advanced genetic and genomic techniques to offer a major step forward in understanding and diagnosing infectious intestinal diseases. The large-scale study analyzed more than 1,000 ...
The MarketWatch News Department was not involved in the creation of this content. First-of-its-kind 1,000-patient clinical study will use RNA-based stool and saliva tests to detect colon polyps -- ...
When David Thau, a lobbyist in Washington, D.C., was 34, he periodically experienced pain in his stomach, irregular bowel movements, blood in his stool and vomiting, and he visited doctors ...
Diagnostics startup Geneoscopy earned its first-ever FDA approval this week. The St. Louis-based company received approval for ColoSense, its noninvasive colorectal cancer screening test. The test — ...
Study aims to enhance colorectal cancer prevention by identifying polyp molecular signals, offering improved sensitivity over at-home DNA tests, which have limited ability to detect precancerous ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results